Our results tend to support these overall findings of reliable remodelling of DBM to new bone. The histological analysis showed significant new bone formation and decreasing residual DBM material in ...
The schematic illustration of the synthesis process of Qx-D (A) and the rat model of femoral infectious bone defect (B). In the realm of orthopedic medicine, the challenge of managing infected bone ...
MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of ...
Tumor cells are known to be fickle sleeper agents, often lying dormant in distant tissues for years before reactivating and forming metastasis. Numerous factors have been studied to understand why the ...
Molecular Matrix, a privately held company that arose from the University of California, Davis, received FDA approval for its Osteo-P bone graft substitute technology. Osteo-P is a non-mineralized, ...
As previously disclosed, in late Q3 2022, the Company began to experience material supply issues related to its ALLOCYTE ® Advanced Cellular Bone Matrix (“ALLOCYTE”) product line. The supply ...
Ossium Health®, a bioengineering company that established a first-of-its-kind bone marrow banking platform, has entered into a collaborative agreement with Extremity Medical, an orthopedic device ...
Nine patients (6 male and 3 female, 30 to 64 years old) that were scheduled for elective removal of dorsal instrumentation hardware over a 12-month time period were included in our study. Indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback